Difficulty: Medium
Average Score: 65%
Practice
Hepatic fibrosis that leads to portal hypertension is a usual finding in
Correct answer
D
Rationale
In the context of pediatric pharmacology, understanding genitourinary assessment is crucial for identifying and managing conditions affecting the kidneys and associated structures. In this scenario, the correct answer is D) autosomal recessive polycystic kidney disease (ARPKD).
Hepatic fibrosis leading to portal hypertension is a common complication of ARPKD due to the congenital hepatic fibrosis associated with this condition. The renal cysts in ARPKD can lead to biliary ductal plate malformation, resulting in fibrosis. This understanding highlights the importance of recognizing this association in pediatric patients with kidney diseases.
Regarding the other options:
A) Poland syndrome: This condition is characterized by the absence or underdevelopment of chest muscles, not associated with hepatic fibrosis or portal hypertension.
B) VACTERL association: This is a cluster of congenital anomalies involving vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies, and limb abnormalities. While renal anomalies are part of VACTERL, hepatic fibrosis and portal hypertension are not typical features.
C) Multicystic renal dysplasia: This condition involves non-hereditary cystic kidney disease, but it is not typically associated with hepatic fibrosis and portal hypertension.
Educationally, this question underscores the importance of linking pharmacological knowledge with an understanding of disease pathophysiology. By recognizing the hepatic complications of ARPKD, healthcare providers can implement appropriate monitoring and therapeutic strategies for affected pediatric patients. This reinforces the need for a comprehensive approach to pediatric pharmacology that considers both renal and hepatic manifestations of genetic conditions.
Hepatic fibrosis leading to portal hypertension is a common complication of ARPKD due to the congenital hepatic fibrosis associated with this condition. The renal cysts in ARPKD can lead to biliary ductal plate malformation, resulting in fibrosis. This understanding highlights the importance of recognizing this association in pediatric patients with kidney diseases.
Regarding the other options:
A) Poland syndrome: This condition is characterized by the absence or underdevelopment of chest muscles, not associated with hepatic fibrosis or portal hypertension.
B) VACTERL association: This is a cluster of congenital anomalies involving vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies, and limb abnormalities. While renal anomalies are part of VACTERL, hepatic fibrosis and portal hypertension are not typical features.
C) Multicystic renal dysplasia: This condition involves non-hereditary cystic kidney disease, but it is not typically associated with hepatic fibrosis and portal hypertension.
Educationally, this question underscores the importance of linking pharmacological knowledge with an understanding of disease pathophysiology. By recognizing the hepatic complications of ARPKD, healthcare providers can implement appropriate monitoring and therapeutic strategies for affected pediatric patients. This reinforces the need for a comprehensive approach to pediatric pharmacology that considers both renal and hepatic manifestations of genetic conditions.